Hopital Neurologique Pierre Wertheimer

Bron, Rhone 69677

2 studies enrolling now · 11 studies all time

What they study most

ALS, Alzheimer's Disease, Alzheimers Disease, Alzheimers Disease, Familial, Amyotrophic Lateral Sclerosis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Dementia, Refractory Generalized Myasthenia Gravis, Relapsing-Remitting Multiple Sclerosis

Studies at this site

• A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation — Recruiting now
• A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation — Recruiting now
• Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 — Running, not enrolling
• Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) — Running, not enrolling
• Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) — Completed
• Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP — Completed
• A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) — Completed
• An Efficacy and Safety Study of Ravulizumab in ALS Participants — Stopped early
• Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. — Completed
• 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease — Stopped early
• Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) — Completed